FY2017 EPS Estimates for Portola Pharmaceuticals, Inc. (PTLA) Decreased by William Blair
Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) – Research analysts at William Blair reduced their FY2017 earnings estimates for shares of Portola Pharmaceuticals in a research note issued to investors on Monday. William Blair analyst M. Phipps now expects that the biopharmaceutical company will earn ($4.93) per share for the year, down from their previous forecast of ($4.86). William Blair also issued estimates for Portola Pharmaceuticals’ Q4 2017 earnings at ($1.52) EPS, Q1 2018 earnings at ($1.04) EPS, Q2 2018 earnings at ($0.85) EPS, Q3 2018 earnings at ($0.57) EPS, Q4 2018 earnings at ($0.23) EPS, FY2018 earnings at ($2.66) EPS, FY2020 earnings at $5.89 EPS and FY2021 earnings at $8.59 EPS.
PTLA has been the topic of several other reports. Oppenheimer Holdings, Inc. reissued a “buy” rating and issued a $80.00 target price on shares of Portola Pharmaceuticals in a research note on Wednesday, September 6th. Zacks Investment Research lowered shares of Portola Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. BidaskClub lowered shares of Portola Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 19th. Morgan Stanley reiterated an “overweight” rating and set a $81.00 target price (up from $75.00) on shares of Portola Pharmaceuticals in a report on Friday, October 6th. Finally, Credit Suisse Group upgraded shares of Portola Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $70.00 target price for the company in a report on Wednesday, August 23rd. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Portola Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $65.15.
Shares of Portola Pharmaceuticals (NASDAQ PTLA) opened at $47.75 on Thursday. The company has a debt-to-equity ratio of 0.90, a quick ratio of 4.95 and a current ratio of 4.95. Portola Pharmaceuticals has a 12 month low of $15.68 and a 12 month high of $67.10.
Portola Pharmaceuticals (NASDAQ:PTLA) last announced its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($1.41) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.49) by $0.08. Portola Pharmaceuticals had a negative return on equity of 158.39% and a negative net margin of 938.19%. The firm had revenue of $3.83 million for the quarter, compared to analysts’ expectations of $4.71 million. During the same period last year, the firm earned ($1.64) earnings per share. The company’s revenue for the quarter was down 58.9% compared to the same quarter last year.
Several hedge funds and other institutional investors have recently made changes to their positions in PTLA. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Portola Pharmaceuticals by 14.2% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,078 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 258 shares in the last quarter. Jacobi Capital Management LLC bought a new position in Portola Pharmaceuticals during the 2nd quarter valued at about $125,000. IFP Advisors Inc grew its holdings in Portola Pharmaceuticals by 7.7% during the 2nd quarter. IFP Advisors Inc now owns 2,370 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 170 shares during the last quarter. QS Investors LLC bought a new position in Portola Pharmaceuticals during the 2nd quarter valued at about $147,000. Finally, Canada Pension Plan Investment Board bought a new position in Portola Pharmaceuticals during the 3rd quarter valued at about $178,000. Hedge funds and other institutional investors own 85.80% of the company’s stock.
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Ratings for Portola Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.